TAO Synergies Inc. (TAOX) - Dilution Analysis

10-K filing | 7.5M shares outstanding

10-Q filing | 7.1M shares outstanding

S-3 filing: This S-3 filing registers the resale of up to 22,302,303 shares of common stock issuable upon conversion of Series E convertible preferred stock and exercise of investor and placement agent warrants.

8-K filing: TAO Synergies Inc. entered into a Securities Purchase Agreement to sell Series E convertible preferred stock and warrants in a private placement, with expected gross proceeds of $11.0 million. ($11.0M proceeds)

10-Q filing | 2.5M shares outstanding

S-3 filing: TAO Synergies Inc. files an S-3 to issue up to $100,000,000 of common stock, preferred stock, or debt securities from time to time.

8-K filing: On July 17, 2025, the Company announced aggregate purchases to date of 29,899 TAO tokens totaling approximately $10 million. ($10.0M proceeds)

S-3 filing: This is an S-3 filing registering the resale of up to 5,044,850 shares of common stock issuable upon conversion of Series D Convertible Preferred Stock and exercise of warrants by selling stockholders.

8-K filing: Synaptogenix, Inc. entered into a Securities Purchase Agreement to sell Series D convertible preferred stock and warrants, and a consulting agreement with James Altucher and Z-List Media, issuing warrants for common stock. ($5.5M proceeds)

10-Q filing | 1.4M shares outstanding

10-K filing | 1.4M shares outstanding

10-Q filing | 1.3M shares outstanding

S-3 filing: The filing relates to the resale or disposition of up to 11,934,108 shares of common stock issuable upon conversion of preferred shares and exercise of warrants, with the selling stockholders receiving all proceeds.

8-K filing: Synaptogenix, Inc. entered into a Securities Purchase Agreement to sell Series C convertible preferred stock to accredited investors in a registered direct offering and a concurrent private placement, with expected gross proceeds of $5.0 million. ($5.0M proceeds)

10-Q filing | 1.2M shares outstanding

10-Q filing | 1.0M shares outstanding

8-K filing: Stock split 1-for-25 | Outstanding: 24,089,646 → 963,585

10-K filing | 24.1M shares outstanding

10-Q filing | 20.4M shares outstanding

10-Q filing | 10.2M shares outstanding

10-Q filing | 7.5M shares outstanding

10-K filing | 7.0M shares outstanding

S-3 filing: Synaptogenix, Inc. is filing an S-3 to register the resale of up to 26,125,280 shares of common stock issuable upon conversion of Series B convertible preferred stock and exercise of warrants.

8-K filing: Synaptogenix, Inc. entered into a Securities Purchase Agreement to sell Series B convertible preferred stock and warrants to accredited investors in a private placement expected to close on November 21, 2022, with gross proceeds of $15 million. ($15.0M proceeds)

10-Q filing | 7.0M shares outstanding

10-Q filing | 7.0M shares outstanding

10-Q filing | 6.9M shares outstanding

S-3 filing: Synaptogenix, Inc. files an S-3 form to offer up to $100,000,000 in a combination of common stock, preferred stock, and debt securities.

10-K filing | 6.7M shares outstanding

10-Q filing | 6.2M shares outstanding

10-Q filing | 6.1M shares outstanding

S-1/A filing: This prospectus relates to the proposed resale or other disposition from time to time of up to 3,458,940 shares of Synaptogenix, Inc. common stock.

S-1 filing: This S-1 filing is for a proposed resale of up to 3,458,940 shares of common stock including shares issuable upon exercise of warrants, by selling securityholders.

8-K filing: Warrants to purchase 483,335 shares of common stock of Synaptogenix, Inc. have been exercised, resulting in gross proceeds of approximately $3.8 million for the Company. ($3.8M proceeds)

8-K filing: Synaptogenix, Inc. entered into Securities Purchase Agreements with accredited investors to issue 1,653,281 shares of common stock and warrants at $7.547 per share, expecting gross proceeds of approximately $12.5 million. ($12.5M proceeds)

10-Q filing | 14.0M shares outstanding

S-1/A filing: This prospectus relates to the proposed resale or other disposition from time to time of up to 28,940,152 shares of Synaptogenix, Inc. common stock, $0.0001 par value per share. The Company is not selling any securities under this prospectus and will not receive any of the proceeds from the sale of securities by the selling securityholders, except that the Company may receive up to approximately $37.6 million in aggregate gross proceeds from the exercise of the Warrants.

10-K filing | 14.0M shares outstanding

S-1 filing: This prospectus relates to the proposed resale or other disposition from time to time of up to 28,940,152 shares of Synaptogenix, Inc. common stock.

8-K filing: Synaptogenix, Inc. entered into Securities Purchase Agreements to issue 9,335,533 shares of common stock and warrants at a combined price of $1.50 per share, expecting gross proceeds of approximately $14,000,000. ($14.0M proceeds)

10-Q filing | 5.0M shares outstanding

S-1/A filing: Spin-off of Neurotrope Bioscience from Neurotrope (to become Petros Pharmaceuticals, Inc.). Distribution ratio of one share of common stock for every five shares of Neurotrope common stock.

S-1/A filing: This S-1/A filing details the spin-off of Neurotrope Bioscience from Neurotrope (to become Petros Pharmaceuticals, Inc.). Neurotrope will distribute shares of Common Stock to its holders of common stock and preferred stock based on a ratio of one share of common stock for every five shares of Neurotrope common stock.

S-1 filing: This S-1 filing details the spin-off of Neurotrope Bioscience from Neurotrope, where Neurotrope shareholders will receive shares of Neurotrope Bioscience common stock at a ratio of one share for every five shares of Neurotrope common stock.